抗栓药物联合治疗急性脑梗死

Objective To investigate the efficacy and safety of combinative antithrombotic therapy for patients with acute cerebral infarction who were not eligible for thrombolysis. Methods Eighty-three patients with acute cerebral infarction at six to twelve hours after the onset were randomly allocated into two groups : treat-ment group(n=46) recived batroxobin, aspirin and dipyridamole; control group(n=37) received aspirin. Neuro-logic impairment scole was measured at days 0, and 14. Barthel index of the two groups were observed at days 0 and 90. Blood coagulation action of the treatment group was also measured at days 0,5 and 11. Results In treatment group, the nervous function defect integral examined 14 d after trearment (12.7±6.4 )was markedly decreased than that of control group (20.1±7.2). A remarkable difference (P<0.01 ) was noticed between them. The Barthel index of the treatment group at 90 d after trearment (86.8±12.9 )was markedly increased than that of control group(43.4±15.1 ) (P<0.01 ). The total effective rate of treatment group and control group were 93.5% and 56.8% respectively( P<0.01). Conclusion The efficacy of combinative antithrombotic therapy for patients with acute cerebral infarction who were not eligible for thrombolysis is better than aspirin a-lone. Further more, the risk of bleeding may not increase in combinative antithrombotic therapy.

Combinative antithrombotic therapy for patients with acute cerebral infarction